PRP

[Medical Today = Reporter Shin Chang-ho]

Cell therapy specialist company Prodigene announced on the 18th that it will participate in the 

2025 Korean Aesthetic Surgery & Laser Medicine Society (DAMILAE) Aesthetic Medical Device Expo & Spring Academic Conference.

The event will be held on February 23 at the Yangjae aT Center, Exhibition Halls 1 and 2, as well as Segyero Room and Changjo Room.

The Korean Aesthetic Surgery & Laser Medicine Society (DAMILAE) is the largest aesthetic medical 

academic conference in Korea, sharing the latest medical technologies and global trends in 

dermatology, plastic surgery, obesity treatment, and more.

Last year, the event concluded successfully with approximately 2,500 participants and over 230 companies in attendance.

At this year’s 2025 DAMILAE Conference, Prodigene plans to introduce its proprietary GFC+ technology-based growth factor injection.

Additionally, the company aims to strengthen collaboration with domestic medical professionals and expand its market reach.

Since its establishment in 1998, Prodigene has grown into a leading company in the 

biotechnology industry through continuous research and development in cell therapy and tissue regeneration engineering.

The company was the first in Korea to develop PRP (Platelet-Rich Plasma) tubes and has led

their commercialization in the domestic market.

Since fully launching its PRP business in 2008, Prodigene has been a pioneer in the industry for over a decade, supplying PRP and BMC products.

Prodigene's PRP technology has been recognized globally, obtaining CE certification in Europe and

FDA approval in the United States, solidifying its technological competitiveness.

The company is actively expanding into overseas markets, including Asia, Europe, and North America, 

and has received high recognition in the United States, Canada, and China.

The GFC+ technology to be showcased at this conference features an innovative plasma

separation system, enabling rapid and convenient PRP extraction.

This advancement is expected to enhance procedural convenience for medical professionals and 

create a more effective treatment environment.

A representative from Prodigene stated,

"We continue to advance our technology to ensure the rapid and precise extraction of PRP in medical settings."

They further added,

"Through this conference, we aim to showcase the excellence of our products and strengthen 

collaborations with domestic medical professionals."

Medical Today, Reporter Shin Chang-ho (ssangdae98@mdtoday.co.kr)

Source: Medical Today